Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Woodford Investment Management leads round into OxSyBio, the second Oxford University spinout from Oxford Nanopore founder Hagan Bayley

Oxford 3d bio printer company oxsybio secures ps10m series a led by woodford.png

OxSyBio, an Oxford University biotech spinout company developing 3D printer technology capable of printing biological materials with a diverse range of therapeutic purposes, has secured £10m in Series A financing from Woodford Investment Management alongside new and existing backers.

OxSyBio has a unique 3D printing platform which enables it to assemble the building blocks of life. The synthetic biology company’s ultimate ambition is to fabricate therapeutic tissues for patients using living cells or non-living ‘artificial’ cells, or hybrid materials. These tissues have the potential to revolutionise the growing field of regenerative medicine, allowing for the literal printing of new tissues that can be used to repair or replace parts of the body damaged through disease or injury.

Find out more (OUI website)